SCHEMBL15744796

SCHEMBL15744796

O=C(CC(=O)Oc1ccc2ccccc2c1)Oc1ccc2ccccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.59
MEN1 O00255 4/20 0.59
MAPT P10636 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 3/20 0.56
CYP1A2 P05177 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PTPN7 P35236 1/20 0.55
PPARG P37231 2/20 0.53
HTT P42858 2/20 0.53
NCOA2 Q15596 2/20 0.53
NCOA1 Q15788 2/20 0.53
NCOA3 Q9Y6Q9 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HSD17B10 Q99714 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
NR2E3 Q9Y5X4 1/20 0.53
NCOR2 Q9Y618 1/20 0.53
FAAH O00519 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27631735 0.86 KMT2A (0.58) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL28010902 0.85 TDP1 (0.47) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL11467623 0.85 KMT2A (0.56) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL8556751 0.85 KMT2A (0.56) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL8401001 0.85 KMT2A (0.61) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL4441141 0.85 PDGFRB (0.61) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL38659578 0.85 PDGFRB (0.61) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL10780307 0.85 KMT2A (0.56) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL28110718 0.85 KMT2A (0.56) KMT2AMEN1MAPTTDP1KDM4E
Hydrochloric Acid SCHEMBL28858265 0.83 PDGFRB (0.59) KMT2AMEN1MAPTTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9814696-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-11-14 US disclosed
US-9814696-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-11-14 US disclosed
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2017-03-09 US disclosed
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2017-03-09 US disclosed
US-9532973-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-01-03 US disclosed
US-20150182499-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2015-07-02 US disclosed
US-20150182499-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2015-07-02 US disclosed
US-9006466-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2015-04-14 US disclosed
US-9006466-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2015-04-14 US disclosed
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2014-05-29 US disclosed
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2014-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES BDKRB1, KLK1, SERPINC1 KMT2A 3807/4885MEN1 913/4885MAPT 4804/4885
US-20150182499-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES BDKRB1, SERPINC1, KLK1 KMT2A 3749/4885MEN1 904/4885MAPT 4807/4885
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES BDKRB1, SERPINC1, KLK1 KMT2A 3749/4885MEN1 904/4885MAPT 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.